-
Most Recent
Search Results
240 results for MJN
War (GD) and Games (GME) Lead 10 Dividend Stocks Increasing Payouts
This week’s batch of dividend stocks increasing payouts was led by two companies, one engaged in actual war, and the other that makes its living…
Consumer Staples: One Buy, One Sell
In the consumer staples space, you should feel good about owning General Mills, but think twice about Mead Johnson.
3 Stocks With Big Dividend Growth Potential
These three stocks aren’t currently big payout providers, but their growth bodes well for future dividend increases — and even capital gains.
Kraft Spins Off Snacks, Wisely Bucking 2011 Buyout Boom
While the buyout frenzy still has legs, some companies, like Kraft, appear to be bucking the trend. Here’s why it’s not a bad move.
Is the Baby Bust Finished?
America’s decline in fertility appears to be leveling off, and a new boom could be just a couple years away. If so, what should investors…
Sears Slammed After Store Closings — Tuesday’s IP Market Recap
Sears shares plummet 27% after announcing the company would close 100 to 120 Sears and Kmart locations.
21 Upgraded Blue-Chip Stocks to Buy
After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise rankings for many…
Mead Johnson’s Margins Are Making Abbott Jealous
The profit war is on between the top baby forumula makers.
Abbott Milking More Profits By Imitating Baby Formula Business
Baby formula maker Mead’s rising success has competitor Abbott Laboratories trying desperately to catch some of the momentum, which is showing no signs of slowing…
A Look at the Week Ahead – (BMY, JBL, OSIP, RHT, SQNM, V)
Trading ideas for the week include BMY, JBL, OSIP, RHT, SQNM, and V.
Is Abbott’s Spinoff the Beginning of a Trend?
A look at Abbott Labs’ (ABT) breakup indicates splitting up may be good medicine for other diversified health care companies.
Abbott Labs Spinoff Looks Like the Right Move
Shareholders would likely be better served by the company’s prescription drug business standing alone. Here’s why.
55 Trades to Make Before Earnings Season Ends
Earnings season continues, and I’ve provided you with my most recent grades on 55 stocks; take a look and trade accordingly
Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons
Its deal to buy diabetes-drug maker Amylin will help, given that market’s potential. Still, patent expirations loom large and won’t be easily overcome.
Mead Johnson Bounce Followed J&J Script
Mead Johnson’s recent Enfamil scare sent many investors packing — but those who stuck with the stock could soon be rewarded.
Is Pfizer Move to Sell Non-Pharma Divisions Bad Medicine?
Pfizer has said it will shed its nutritional and animal health businesses to pump more money into its drug pipeline. But is the move risky?
Pfizer Shares – 3 Pros, 3 Cons
Will a robust pipeline offset the loss of patent protection on key drugs?
Will Less Be More for Big Pharma?
Companies seem split on the asset selloff strategy.
The Dow Jones Transportation Average Is Showing Cracks
A breakdown isn’t imminent in the Dow Jones Transportation Average, but traders should keep a close eye on it.
Investing in Generation Y and the Next Great Baby Boom
Much like the Baby Boomers did more to shape the U.S. over the past 50 years, their children — Generation Y — will shape the…
52 Trades to Beat the Mutual Fund Slump
I’ve taken some of the guesswork out of stock picking for you by updating my ratings for these 52 stocks.
Mead Johnson Might Be One to Shed
Sales for Mead Johnson Nutrition’s baby food have been robust, but dividends and earnings growth have been mediocre.
IPOs Investing – Why You Want to Invest in IPOs NOW!
We are looking at the hottest IPO market we have seen in years, and you’ll be kicking yourself if you miss out.
50 Ways to Make Market Swings Work For You
With the stock market moving around in earnings season, now is the time to look through our buy and sell chart looking for ways to…
7 – 10 of 240 results
